Cohort plc (AIM:CHRT)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 496.30M |
| Revenue (ttm) | 270.04M |
| Net Income (ttm) | 19.25M |
| Shares Out | 45.70M |
| EPS (ttm) | 0.44 |
| PE Ratio | 24.54 |
| Forward PE | 18.16 |
| Dividend | 0.16 (1.51%) |
| Ex-Dividend Date | Aug 21, 2025 |
| Volume | 119,672 |
| Average Volume | 153,889 |
| Open | 1,076.00 |
| Previous Close | 1,076.00 |
| Day's Range | 1,066.00 - 1,101.90 |
| 52-Week Range | 963.30 - 1,796.00 |
| Beta | 0.19 |
| RSI | 33.96 |
| Earnings Date | Dec 10, 2025 |
About Cohort
Cohort plc provides various products and services in defense, security, and related markets in the United Kingdom, Germany, Portugal, Australia, North and South America, Asia Pacific, Africa, and other European countries. It operates through Communications and Intelligence; and Sensors and Effectors segments. The company offers chess dynamic, a surveillance and fire control which provides bespoke solutions for land and maritime domains; and and combat systems. It also provides integrated command, control, and communications systems for warships... [Read more]
Financial Performance
In 2025, Cohort's revenue was 270.04 million, an increase of 33.33% compared to the previous year's 202.53 million. Earnings were 19.25 million, an increase of 25.68%.
Financial StatementsNews
Protara Reports Updated Interim Phase 2 Data Of TARA-002 In Non-muscle Invasive Bladder Cancer
(RTTNews) - Protara Therapeutics, Inc. (TARA) has reported new interim results from Cohort A of its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in BCG- naïve patients with high-grade non-muscle invas...
Protara To Present New Interim Phase 2 Data Of TARA-002 In Bladder Cancer Next Month
(RTTNews) - Protara Therapeutics Inc. (TARA) is scheduled to present new interim data from Cohort A of its ongoing Phase 2 trial assessing investigational cell-based therapy, TARA-002, in patients wit...
Cohort Issues Statement On Current Trading And Outlook; FY26 Growth Expectations Remains Unchanged
(RTTNews) - Cohort said it achieved record financial results in the year ended 30 April 2025, with strong performances in revenue, adjusted operating profit, order intake, adjusted EPS, and net funds....
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refractoriness and Refractory Antiphospholipid Syndrome – – Data Readouts Expecte...
Cohort plc: High Growth Aerospace And Defense Play With Steep Valuation
Cohort plc has seen significant growth, with revenues up 25% and profits up 68% in the last six months. Learn more about COHTF stock here.
Cohort expands global reach Down Under with new acquisition
Cohort has completed the acquistion of Australia's EM Solutions, enhancing naval defence capabilities after a record year's results
U.S. Global Launches Technology And Aerospace & Defense ETF: Why Its Allocation Makes Sense
The launch of the U.S. Global Technology and Aerospace & Defense ETF (NYSE: WAR) on Dec. 30, 2024, and its subsequent debut on the New York Stock Exchange, is another feather in the cap for U.S. Glob...
Half Year 2025 Cohort PLC Earnings Presentation Transcript
Half Year 2025 Cohort PLC Earnings Presentation Transcript
Half Year 2025 Cohort PLC Analyst presentation Q&A Transcript
Half Year 2025 Cohort PLC Analyst presentation Q&A Transcript
Visa Accelerator Program Africa selects Cohort 3
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients
Theriva Biologics announces DSMC approval to proceed to Cohort ... Full story available on Benzinga.com
Hub71 welcomes 21 startups in 15th Cohort to Abu Dhabi that have raised over $130mln in funding
Cohort 15 startups have raised over USD 130 million in capital, with 80 per cent of selected startups headquartered outside the UAE, reinforcing Hub71's ability to attract high-potential international...